Results 91 to 100 of about 1,551 (185)
The Application of High-Resolution Mass Spectrometry for the Analysis of Biopolymers, Metabolites, and Biologically Relevant Small Molecules [PDF]
High-resolution mass spectrometry (HRMS), as its name suggests, possesses high resolving power that enables the separation of ions with very close mass values.
Tran, Christ Duc
core +1 more source
Non‐coding RNAs to treat vascular smooth muscle cell dysfunction
British Journal of Pharmacology, Volume 182, Issue 2, Page 246-280, January 2025.Vascular smooth muscle cell (vSMC) dysfunction is a critical contributor to cardiovascular diseases, including atherosclerosis, restenosis and vein graft failure. Recent advances have unveiled a fascinating range of non‐coding RNAs (ncRNAs) that play a pivotal role in regulating vSMC function.
Simon D. Brown +4 more
wiley +1 more source
Implications of siRNA Therapy in Bone Health: Silencing Communicates
BiomedicinesThe global statistics of bone disorders, skeletal defects, and fractures are frightening. Several therapeutic strategies are being used to fix them; however, RNAi-based siRNA therapy is starting to prove to be a promising approach for the prevention of ...
Puneetpal Singh +7 more
doaj +1 more source
Discover MedicineRNA interference (RNAi) has emerged as a revolutionary therapeutic approach for silencing disease-associated genes with unprecedented specificity and precision.
Sarfaraz K. Niazi
doaj +1 more source
The Risks of miRNA Therapeutics: In a Drug Target Perspective
Drug Design, Development and Therapy, 2021 Song Zhang, 1, 2 Zhujun Cheng, 3 Yanan Wang, 1 Tianyu Han 1 1Jiangxi Institute of Respiratory Disease, The First Affiliated Hospital of Nanchang University, Nanchang, 330006, People’s Republic of China; 2College of Pharmaceutical Sciences ...
Zhang S, Cheng Z, Wang Y, Han T
doaj
RNA interference therapy in cardiology: will new targets improve therapeutic goals?
Drugs in ContextThe discovery of RNA interference in 1998 opened avenues for the manipulation of gene expression, leading to the development of small interfering RNA (siRNA) drugs.
Renata TJ Fazoli +3 more
doaj +1 more source
Journal of Rare DiseasesBackground Acute intermittent porphyria (AIP) is a rare metabolic disorder caused by deficiency of hydroxymethylbilane synthase (HMBS), leading to accumulation of neurotoxic heme precursors. Its protean neurovisceral manifestations and the possibility of
Bhupender Arya +4 more
doaj +1 more source
UEG Week 2025 Poster Presentations
United European Gastroenterology Journal, Volume 13, Issue S8, Page S803-S1476, October 2025.
wiley +1 more source
Antisense oligonucleotides: a novel Frontier in pharmacological strategy [PDF]
, 2023 Bertocchi, I., Collino, M., Collotta, D.
core +1 more source
When Carbohydrates are Not Enough: Acute Intermittent Porphyria Treated with Givosiran [PDF]
, 2022 Kate, Yugandhara +3 more
core +1 more source